Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Liabilities (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Total Liabilities for 14 consecutive years, with $202.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 14.32% year-over-year to $202.9 million, compared with a TTM value of $202.9 million through Dec 2025, down 14.32%, and an annual FY2025 reading of $216.0 million, down 12.84% over the prior year.
  • Total Liabilities was $202.9 million for Q4 2025 at Enanta Pharmaceuticals, down from $216.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $257.3 million in Q2 2023 and bottomed at $31.7 million in Q1 2021.
  • Average Total Liabilities over 5 years is $150.2 million, with a median of $209.5 million recorded in 2025.
  • The sharpest move saw Total Liabilities fell 16.92% in 2022, then skyrocketed 445.34% in 2023.
  • Year by year, Total Liabilities stood at $56.2 million in 2021, then decreased by 16.92% to $46.7 million in 2022, then skyrocketed by 406.7% to $236.6 million in 2023, then grew by 0.09% to $236.8 million in 2024, then decreased by 14.32% to $202.9 million in 2025.
  • Business Quant data shows Total Liabilities for ENTA at $202.9 million in Q4 2025, $216.0 million in Q3 2025, and $221.8 million in Q2 2025.